ARTICLE | Company News
Despite manufacturing concern, Acacia still expects 1H19 launch for PONV therapy
October 8, 2018 6:21 PM UTC
Acacia Pharma Group plc (Euronext:ACPH) said FDA raised a concern related to manufacturing deficiencies in a complete response letter issued Monday for an NDA seeking approval of Barhemsys amisulpride to treat and prevent postoperative nausea and vomiting.
Acacia, which lost €0.91 (23%) to €3.04 on Monday, said it still anticipates a 1H19 launch of the product...
BCIQ Company Profiles